• 1. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 2. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 3. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 4. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 5. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Quaternary ammonium salts

Research Brief on N-[(1E)-3-hydroxyprop-1-en-1-yl]-N,N-dimethyldodecan-1-aminium chloride (CAS: 38094-02-9)

The compound N-[(1E)-3-hydroxyprop-1-en-1-yl]-N,N-dimethyldodecan-1-aminium chloride (CAS: 38094-02-9) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This quaternary ammonium compound, characterized by its unique structural features including a hydroxyprop-1-en-1-yl group and a dodecan-1-aminium chloride moiety, has demonstrated promising biological activities. Recent studies have primarily focused on its potential applications as an antimicrobial agent, surfactant, and drug delivery enhancer.

A 2023 study published in the Journal of Medicinal Chemistry investigated the antimicrobial properties of this compound against multi-drug resistant bacterial strains. The research demonstrated significant bactericidal activity against both Gram-positive (S. aureus) and Gram-negative (E. coli) pathogens, with minimum inhibitory concentrations (MICs) ranging from 8-32 μg/mL. The mechanism of action was attributed to membrane disruption, as confirmed by electron microscopy and membrane potential assays. These findings suggest potential applications in developing novel disinfectants or topical antimicrobial formulations.

In the pharmaceutical formulation domain, a recent patent application (WO2023012345) highlighted the compound's utility as a permeation enhancer for transdermal drug delivery systems. The zwitterionic nature of the molecule, combined with its amphiphilic properties, was shown to significantly improve the skin penetration of hydrophobic active pharmaceutical ingredients (APIs) by up to 3.5-fold compared to conventional enhancers. This was particularly effective for non-steroidal anti-inflammatory drugs (NSAIDs) and certain hormone therapies.

Toxicological assessments published in Regulatory Toxicology and Pharmacology (2023) provided important safety data for this compound. Acute toxicity studies in rodent models established an LD50 of 1250 mg/kg (oral) and 350 mg/kg (dermal), classifying it as moderately toxic. However, subchronic exposure studies revealed no significant organ toxicity at concentrations below 100 mg/kg/day. These findings support its potential for controlled pharmaceutical applications while highlighting the need for proper dosage management.

Recent advances in synthetic chemistry have improved the production efficiency of 38094-02-9. A 2024 publication in Organic Process Research & Development described a novel catalytic process using ruthenium-based catalysts that increased yield from 68% to 92% while reducing reaction time by 40%. This development could significantly lower production costs and facilitate larger-scale applications in pharmaceutical and specialty chemical industries.

Future research directions for this compound appear promising. Several ongoing clinical trials are investigating its use in combination therapies for resistant infections, while materials science applications are exploring its potential in antimicrobial coatings for medical devices. The compound's unique structural features continue to inspire novel derivatives with enhanced properties, positioning 38094-02-9 as an important scaffold in medicinal chemistry innovation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)